Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD52 | P43351 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 11/20 | 0.86 |
| ▸ | DRD2 | P14416 | 11/20 | 0.84 |
| ▸ | DRD5 | P21918 | 1/20 | 0.77 |
| ▸ | DRD3 | P35462 | 1/20 | 0.77 |
| ▸ | HTR1A | P08908 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Xylopinine SCHEMBL910941 | 1.00 | RAD52 (1.00) | RAD52DRD1DRD2DRD5DRD3 | |
| Xylopinine SCHEMBL24696331 | 1.00 | RAD52 (1.00) | RAD52DRD1DRD2DRD5DRD3 | |
| Xylopinine SCHEMBL30473255 | 1.00 | RAD52 (1.00) | RAD52DRD1DRD2DRD5DRD3 | |
| Xylopinine SCHEMBL29999174 | 1.00 | RAD52 (1.00) | RAD52DRD1DRD2DRD5DRD3 | |
| SCHEMBL123459 | 0.93 | DRD1 (1.00) | RAD52DRD1DRD2DRD5DRD3 | |
| SCHEMBL14235276 | 0.93 | DRD1 (1.00) | RAD52DRD1DRD2DRD5DRD3 | |
| SCHEMBL30473248 | 0.92 | DRD2 (1.00) | RAD52DRD1DRD2DRD5DRD3 | |
| Discretine SCHEMBL29408007 | 0.92 | DRD2 (1.00) | RAD52DRD1DRD2DRD5DRD3 | |
| SCHEMBL29999733 | 0.92 | DRD2 (1.00) | RAD52DRD1DRD2DRD5DRD3 | |
| SCHEMBL910848 | 0.92 | DRD2 (1.00) | RAD52DRD1DRD2DRD5DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109260216-A | It is a kind of to be poisoned the neuroprotective agent and application thereof of tardy cerebral injury for CO | 朱秀丽 | 2019-01-25 | — | — | CN | claimed |
| CN-106728296-A | It is a kind of to prevent and treat pharmaceutical composition of fibroid and preparation method thereof | 济南昊雨青田医药技术有限公司 | 2017-05-31 | — | — | CN | claimed |
| CN-106727861-A | It is a kind of to treat pharmaceutical composition of parotitis and preparation method thereof | 济南昊雨青田医药技术有限公司 | 2017-05-31 | — | — | CN | claimed |
| CN-106668346-A | Pharmaceutical composition capable of preventing and treating thyroid gland diseases | 济南昊雨青田医药技术有限公司 | 2017-05-17 | — | — | CN | claimed |
| CN-106620055-A | Pharmaceutical composition for treating diabetic retinopathy and preparation method of pharmaceutical composition | 济南昊雨青田医药技术有限公司 | 2017-05-10 | — | — | CN | claimed |
| CN-106109606-A | A kind of pharmaceutical composition treating colon cancer and preparation method thereof | 济南星懿医药技术有限公司 | 2016-11-16 | — | — | CN | claimed |
| CN-105663216-A | Drug combination for treating coronary heart disease angina and preparation method thereof | 济南星懿医药技术有限公司 | 2016-06-15 | — | — | CN | claimed |
| CN-105641016-A | Pharmaceutical composition for treating coronary heart disease | 济南星懿医药技术有限公司 | 2016-06-08 | — | — | CN | claimed |
| CN-105287711-A | Medicinal composition for treating dyspepsia | JINAN XINGYI MED TECH CO LTD | 2016-02-03 | — | — | CN | claimed |
| CN-105250388-A | Medicine composition for treating chronic bacterial prostatitis and preparation method thereof | JINAN XINGYI MED TECH CO LTD | 2016-01-20 | — | — | CN | claimed |
| CN-1116040-C | Medicinal composition and its antalgic purpose | QU RIQIAN (CN) | 2003-07-30 | — | — | CN | claimed |
| CN-1305811-A | Medicinal composition and its antalgic purpose | QU RIQIAN (CN) | 2001-08-01 | — | — | CN | claimed |
| CN-1042895-C | Medicines composition and its method for treating drop syndrome and de-addiction of drugaddict | QU RIQIAN (CN) | 1999-04-14 | — | — | CN | claimed |
| US-5547956-A | ADMINISTERING TO PATIENT ACONITANE DERIVATIVES AND THEIR INORGANIC SALTS AND TETRAHYDROPROTOBERBERINE DERIVATIVES; SIDE EFFECT REDUCTION | Qu, Yueqian (CN) | 1996-08-20 | — | — | US | claimed |
| CN-1087516-A | Pharmaceutical composition and be used for the treatment of the method for junkie withdrawal syndrome and withdrawal | QU YUEQIAN (CN) | 1994-06-08 | — | — | CN | claimed |
| US-5153178-A | Inotropic agent for the heart of a mixture of a glycoside and a protoberberine alkaloid | MAROKO, ROBERT | 1992-10-06 | — | — | US | claimed |
| US-11731965-B2 | Tetrahydroprotoberberine compound, preparation method therefor and uses thereof, and pharmaceutical composition | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2023-08-22 | — | — | US | disclosed |
| CN-109260216-B | Nerve protective agent for delayed brain injury caused by CO poisoning and application thereof | 朱秀丽 | 2021-05-07 | — | — | CN | disclosed |
| EP-0108147-A1 | Use of a protoberberine alkaloid and composition containing same. | MAROKO PETER R | 1984-05-16 | — | — | EP | disclosed |
| WO-1983003970-A1 | COMPOUNDS, COMPOSITIONS AND METHOD OF TREATMENT FOR IMPROVING CIRCULATORY PERFORMANCE | MAROKO PETER R | 1983-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731965-B2 | Tetrahydroprotoberberine compound, preparation method therefor and uses thereof, and pharmaceutical composition | NOTUM, BHMT, CYP4F11 | RAD52 3324/4885DRD1 448/4885DRD2 682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.